Categories: News

Disclosure Under Chapter 9 Section 5 of the Securities Market Act (BlackRock, Inc.)

SAMPO PLC                 STOCK EXCHANGE RELEASE       19 January 2021 at 3:50 pm

Disclosure Under Chapter 9 Section 5 of the Securities Market Act (BlackRock, Inc.)

Sampo plc (business code 0142213-3) has received a disclosure under Chapter 9, Section 5 of the Securities Markets Act, according to which the total number of Sampo A shares (ISIN: FI009003305) owned directly, indirectly or through financial instruments by BlackRock, Inc. (USA tax ID 32-0174421) and its funds decreased on 18 January 2021 below five (5) per cent of Sampo plc’s total stock.

Sampo’s share capital comprises 555,351,850 shares, of which 554,151,850 are A shares and 1,200,000 are B shares. Each A share entitles its holder to one (1) vote and each B share to five (5) votes. Thus, the total number of votes is 560,151,850.

Total positions of BlackRock, Inc and its funds subject to the notification:

  % of shares and voting rights (total of A) % of shares and voting rights through financial instruments (total of B) Total of both in % (A+B)
Resulting situation on the date on which threshold was crossed or reached Below 5% shares

Below 5% voting rights

Below 5% shares

Below 5% voting rights

Below 5% shares

Below 5% voting rights

Positions of previous notification (if applicable) 4.99% shares

Below 5% voting rights

0.02% shares

Below 5% voting rights

5.01% shares

Below 5% voting rights

Notified details of the resulting situation on the date on which the threshold was crossed:

A: Shares and voting rights:

Class/type of shares
ISIN code
Number of shares and voting rights % of shares and voting rights
  Direct
(SMA 9:5)
Indirect
(SMA 9:6 and 9:7)
Direct
(SMA 9:5)
Indirect
(SMA 9:6 and 9:7)
FI0009003305   Below 5% shares

Below 5% voting rights

  Below 5% shares

Below 5% voting rights

SUBTOTAL A Below 5% shares

Below 5% voting rights

Below 5% shares

Below 5% voting rights

B: Financial instruments according to SMA 9:6a:

Type of financial
instrument
Expiration date Exercise/
Conversion Period
Physical or
cash settlement
Number of shares
and voting rights
% of shares and
voting rights
American Depository Receipt (US79588J1025) N/A N/A Physical Below 5% shares

Below 5% voting rights

Below 5% shares

Below 5% voting rights

Securities Lent N/A N/A Physical Below 5% shares

Below 5% voting rights

Below 5% shares

Below 5% voting rights

CFD N/A N/A Cash Below 5% shares

Below 5% voting rights

Below 5% shares

Below 5% voting rights

      SUBTOTAL B Below 5% shares

Below 5% voting rights

Below 5% shares

Below 5% voting rights

SAMPO PLC

Jarmo Salonen
Head of Investor Relations and Group Communications
tel. +358 10 516 0030

Distribution:
Nasdaq Helsinki
London stock exchange
The principal media
Financial Supervisory Authority
www.sampo.com

Staff

Recent Posts

RAAPID Raises Series A from M12, Microsoft’s Venture Fund to Scale Next-Generation Healthcare Risk Adjustment

Company reports 300% revenue growth in 2024 and advances partnerships with nation's leading health systems…

1 hour ago

Anatomage Announces Acquisition of Cloud-based Software Company BioDigital

SANTA CLARA, Calif., Jan. 10, 2025 /PRNewswire/ -- Anatomage Inc., a leader in medical education…

1 hour ago

Avantor® to Report Fourth Quarter and Full Year 2024 Earnings on Friday, February 7, 2025

RADNOR, Pa., Jan. 10, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider…

1 hour ago

Cmbio® Acquires Eagle Genomics’ Assets to Enhance Multi-Omics Software and AI/ML capabilities of its Digital Biology Platform.

COPENHAGEN, Denmark, Jan. 10, 2025 /PRNewswire/ -- Cmbio®, a global leader in multi-omics science and…

1 hour ago

The New York Stem Cell Foundation Research Institute Enters Agreement to Accelerate Precision Drug Discovery for Neurodegenerative Disease

Partnership Will Harness NYSCF's Automated Cell Culture Systems and Artificial Intelligence Capabilities to Study Disease at…

1 hour ago

Bio-Techne Expands R&D Systems AI-Engineered Designer Protein Portfolio to Advance Cell Therapy and Regenerative Medicine

MINNEAPOLIS, Jan. 10, 2025 /PRNewswire/ -- Bio-Techne (NASDAQ: TECH), a global leader in life science…

1 hour ago